Latest Articles

Publication Date
Correction: Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis - Cell Communication and Signaling

Correction: Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis Cell Communication and Signaling

Published: Oct. 24, 2025, 12:50 p.m.
Roche axes 4 Chugai solid tumor assets in early-phase clearout - Fierce Biotech

Roche axes 4 Chugai solid tumor assets in early-phase clearout Fierce Biotech

Published: Oct. 23, 2025, 8:53 a.m.
Roche axes 4 Chugai solid tumor assets in early-phase clear-out - Fierce Biotech

Roche axes 4 Chugai solid tumor assets in early-phase clear-out Fierce Biotech

Published: Oct. 23, 2025, 8:53 a.m.
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - BioSpace

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer BioSpace

Published: Oct. 20, 2025, 4:42 a.m.
Shaoyao Gancao Decoction: a comprehensive review of modern clinical applications and underlying pharmacological mechanisms.

Shaoyao Gancao Decoction, a classic formula from Zhang Zhongjing in the Han Dynasty, has the effects of regulating the function of the liver, relieving spasm and stopping pain. Traditionally, it …

Published: Oct. 20, 2025, midnight
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - Lelezard

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Lelezard

Published: Oct. 18, 2025, 12:47 p.m.
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - The AI Journal

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer The AI Journal

Published: Oct. 18, 2025, 10:20 a.m.
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - GlobeNewswire

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer GlobeNewswire

Published: Oct. 18, 2025, 10 a.m.
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - Yahoo Finance

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Yahoo Finance

Published: Oct. 18, 2025, 10 a.m.
Addressing Meta-Inflammation in the Comprehensive Management of Chronic Pain.

Chronic pain is a widespread condition affecting millions globally, placing significant strain on healthcare systems, as evidenced by the current opioid crisis. Despite advances in pain management, conventional treatments often …

Published: Oct. 18, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!